Selected contemporary clinical studies for newly diagnosed older HL patients in advanced stages
| Reference . | N . | Therapy . | Outcomes . | Febrile neutropenia (%) . | Peripheral neuropathy (≥grade 3; %) . | TRM (%) . |
|---|---|---|---|---|---|---|
| Forero-Torres et al37 | 27 | BV | 2-y PFS, ∼30% | 0 | 26 | NR |
| 2-y OS, NR | ||||||
| Friedberg et al38 | 42 | BV + bendamustine or dacarbazine | 2-y PFS, ∼50% | NR | 21 | NR |
| 2-y OS, NR | ||||||
| Evens et al26 | 48 | BV sequentially with AVD | 2-y PFS, 84% | 8 | 4 | 2 |
| 2-y OS, 93% | ||||||
| Böll et al49 | 25 | Lenalidomide + AVD | 3-y PFS, 70% | 4 | NR | NR |
| 3-y OS, 84% | ||||||
| Evens et al51 | 84 | A+AVD | 2-y mPFS, 70.3% | 37 | 18 | 4 |
| 102 | ABVD | 2-y OS, NR | 17 | 3 | 5 | |
| 2-y mPFS, 71.4% | ||||||
| 2-y OS, NR | ||||||
| Boell et al50 | 49 | BV + CAP | 1-y PFS, 73.9% | 27 | 0 | 2 |
| 1-y OS, 92.6% |
| Reference . | N . | Therapy . | Outcomes . | Febrile neutropenia (%) . | Peripheral neuropathy (≥grade 3; %) . | TRM (%) . |
|---|---|---|---|---|---|---|
| Forero-Torres et al37 | 27 | BV | 2-y PFS, ∼30% | 0 | 26 | NR |
| 2-y OS, NR | ||||||
| Friedberg et al38 | 42 | BV + bendamustine or dacarbazine | 2-y PFS, ∼50% | NR | 21 | NR |
| 2-y OS, NR | ||||||
| Evens et al26 | 48 | BV sequentially with AVD | 2-y PFS, 84% | 8 | 4 | 2 |
| 2-y OS, 93% | ||||||
| Böll et al49 | 25 | Lenalidomide + AVD | 3-y PFS, 70% | 4 | NR | NR |
| 3-y OS, 84% | ||||||
| Evens et al51 | 84 | A+AVD | 2-y mPFS, 70.3% | 37 | 18 | 4 |
| 102 | ABVD | 2-y OS, NR | 17 | 3 | 5 | |
| 2-y mPFS, 71.4% | ||||||
| 2-y OS, NR | ||||||
| Boell et al50 | 49 | BV + CAP | 1-y PFS, 73.9% | 27 | 0 | 2 |
| 1-y OS, 92.6% |
The studies included a minimum 25 patients.
A+AVD, BV + doxorubicin, vinblastine, and dacarbazine; CAP, cyclophosphamide, doxorubicin, and prednisone; mPFS, modified PFS; NR, not reported; OS, overall survival.